Shardul Amarchand Mangaldas & Co (SAM) has advised private equity major Advent International on the purchase of a 50.1 percent stake in India’s Suven Pharmaceuticals, with Cyril Amarchand Mangaldas (CAM) advising the sellers, the Jasti family.

According to Reuters, Advent is expected to make an additional open offer for up to 26 percent of the voting share capital held by public shareholders. Advent intends to explore merging Suven with its wholly owned Cohance Lifesciences to build a company that specializes in active pharmaceutical ingredients as well as contract development and manufacturing businesses, Reuters added.

The CAM team was led by partner Shishir Vayttaden, with support from partners Namrata Kolar, Biplab Lenin, and Avaantika Kakkar.